IN8bio cuts staff and pipeline to focus on AML cell therapy
The company has reduced its headcount by approximately 49% and suspended enrolment in a Phase II glioblastoma trial.
Immuno
UCLA Health to begin trial of personalised brain cancer vaccine
Ultimovacs cancer vaccine fails in Phase II trial for head and neck cancer
Immorna Biotherapeutics granted FDA IND clearance for Phase I/II JCXH-211 study
Anti-obesity drugs will be 2024’s defining trend
ASCO24: AbbVie flexes early success of ADC pipeline in solid tumours
ASCO24: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC
ASCO24: MSD’s ADC shows efficacy in lung and breast tumours
